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expenditures in the ≤ 62 cohort. CONCLUSIONS: HE is a growing problem in the US 
and becoming increasingly costly condition for the Medicare population.
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OBJECTIVES: Estimating health-related utility weights in Crohn’s Disease (CD) 
patients is crucial for assessing the cost-effectiveness of new pharmaceutical 
interventions. However, values used in these analyses are usually based on sec-
ondary data and vary substantially among studies. We estimated utility weights 
in a consecutive sample of real-world CD patients. METHODS: Patients enrolled 
in an ongoing socio-economic study of CD in the Israeli adult patient population 
completed the self-administered SF-36 questionnaire and were assessed for their 
current clinical status, including the Harvey-Bradshaw Index (HBI) of disease sever-
ity. Patients were classified to one of the four disease states: disease remission 
(HBI< 5); mild disease (HBI 5-7); moderate disease (HBI 8-16), and severe disease 
(HBI> 16). For each patient enrolled we calculated a utility weight using the SF-6D 
preference-based scoring system developed by Brazier et al. RESULTS: The cohort 
comprised of 373 patients: (39.4% male), with mean age of 37.8 (±14.2) years, 14.5 
(±2.8) years of education, and 11.8 (±9.0) years elapsed since first diagnosis. The 
average HBI was 6.7 (± 5.6); 148 patients were in remission state, 79 had mild disease, 
121 moderate and 25 severe disease. The SF-6D utility weights were correlated with 
the HBI (-0.341; p< 0.0001). The mean utility weights for each disease state were 
as follows: disease remission: 0.720 (±0.141); mild disease; 0.700 (±0.123); moder-
ate disease: 0.603 (±0.109); severe disease: 0.531 (±0.135); p< 0.001. The significant 
predictors of utility weights in a multivariable regression analysis were the HBI 
(β = -0,440; p< 0.001), years of education (β = 0.104; p= 0.034), and time since diagnosis 
(β = 0.150; p= 0.007); (R2 = 0.246). CONCLUSIONS: CD patients suffer from a deprived 
quality of life even in the remission and mild stages of the disease. Utility weights 
for these patients were generally lower as compared to values used in published 
cost-effectiveness analyses. These values should be considered when assessing the 
value for money of future interventions for CD.
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OBJECTIVES: Eosinophilic Esophagitis (EoE) is an inflammatory disorder that can 
have an impact on quality of life in individuals. The psychometric properties of 
the Dysphagia Symptom Questionnaire (DSQ) were assessed in a Phase 2, ran-
domized, double-blind, placebo controlled study of oral budesonide suspension 
with an open-label extension program. METHODS: The evaluation focused on three 
items of the DSQ. Psychometric data were analyzed against the FDA guidance and 
included item level analysis as well as score validation including floor/ceiling, item 
discrimination, construct validity (concurrent validity and known group’s method), 
test-retest reliability, responsiveness, and calculation of minimally important differ-
ences (MID). RESULTS: Patients were 69% male, 62% age ≥ 18, 95% white. Test-retest 
reliability was strong (r= 0.82). Floor/ceiling levels were below the criteria (≤ 9%) for all 
items (range 6.5-8.6%). There was strong item discrimination with 98.1% of patients 
indicating dysphagia in the quartile of DSQ scores. Physician’s global ratings of 
severity and EoE symptom scores were consistent with monotonically increasing 
DSQ scores. Anchor-based MIDs were 6.5 “a little better” and 13.5 “better” respec-
tively. CONCLUSIONS: The DSQ is a reliable and valid measure able to clinically 
discriminate patients along the continuum of dysphagia severity.
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OBJECTIVES: To study the variations in self-reported health status of mainland 
Chinese patients with chronic hepatitis B (CHB) prior to initiating nucleos(t)ide 
analogues (NUC) treatment. METHODS: This study drew the baseline data of the 
EVOLVE study, an ongoing observational clinical study of NUCs for treating CHB 
patients with or without compensated cirrhosis in China. All patients underwent a 
basket of tests for liver functions and information on their clinical characteristics, 
life styles, health status (using the EQ-5D-3L questionnaire), and socio-economic 
status was obtained from medical records or personal interviews. Variations in self-
reported health problems and global health were analyzed with logistic and linear 
regression models, respectively, to identify significant predictors using a stepwise 
selection method. RESULTS: Two thousand nine hundred and fifty-eight of the 
3,434 NUC naïve CHB patients enrolled from 63 hospitals across China (mean age: 
39.3 years; male: 73.1%; HBeAg positive: 61.1%; compensated cirrhosis: 20.4%) were 
included in this analysis. Among those, less than 2% reported problems in mobility, 
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OBJECTIVES: The approval of direct-acting antivirals for Interferon-free treatment 
revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two 
treatment regimens for genotype 1 infection received approval in the European 
Union: Sofosbuvir and Ribavirin for 24 weeks and Sofosbuvir and Simeprevir with or 
without Ribavirin for 12 weeks. We aim to analyze the cost-effectiveness of both reg-
imens in Germany. METHODS: We set up a Markov model with a lifetime horizon to 
simulate immediate treatment success and long-term disease progression for treat-
ment-naive patients. The model analyzes both shortterm and longterm costs and 
benefits from the perspective of the German Statutory Health Insurance. We apply 
the efficiency frontier method, which was suggested by German Institute for Quality 
and Efficiency in Health Care for cost-effectiveness analysis in Germany. RESULTS: 
The efficiency frontier is defined by dual therapy and first generation direct-acting 
antiviral Boceprevir, yielding a maximum of € 1,447.69 per additional percentage 
point of sustained virologic response gained. Even without rebates, Sofosbuvir/
Simeprevir is very close with € 1,560.13 per additional percentage point. It is both 
more effective and less expensive than Sofosbuvir/Ribavirin. CONCLUSIONS: In 
addition to higher sustained virologic response rates, new direct-acting antivirals 
save long-term costs by preventing complications such as liver cirrhosis, hepa-
tocellular carcinoma and ultimately liver transplants, thereby offsetting part of 
higher drug costs. Our findings are in line with the guidance published by German 
Society for Gastroenterology, Digestive and Metabolic Diseases, which recommends 
Sofosbuvir/Simeprevir for Interferon ineligible or intolerant patients.
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OBJECTIVES: This study reports the long-term cost per sustained virologic response 
(SVR) with Viekira Pak (ombitasvir, paritaprevir and ritonavir, dasabuvir) with and 
without ribavirin and standard of care in the US, including sofosbuvir plus sime-
previr (SOF+SMV) and sofosbuvir plus peg-interferon and ribavirin (SOF+PR), among 
patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. METHODS: 
A Markov cost-effectiveness model was used to estimate the long-term cost of HCV. 
The analysis modeled independent cohorts of GT1 HCV patients over a lifetime 
horizon with annual cycles from a US payer perspective. Liver disease progression 
was assessed based on previous natural history model. Direct medical costs (in 2014 
prices and discounted at 3% per year) were obtained from the published literature. 
Efficacy and safety data were obtained from published clinical trials. SVR rates 
were stratified by patient treatment history, cirrhosis status, and sub-genotype, 
where available. Long-term cost per SVR for a patient segment was calculated by 
dividing total cost of HCV over patient’s lifetime by the mean SVR rate in that 
patient segment. RESULTS: The long-term cost per SVR with Viekira Pak ranged 
from $88,305 to $94,433 in GT1 non-cirrhotic patients (12-week regimen), $125,748 
(12-week) to $216,520 (24-week) in GT1 cirrhotic patients, $94,433 to $141,413 in GT1a 
and $88,332 to $125,748 in GT1b treatment-naïve patients (12-week). Long-term 
cost per SVR with SOF+SMV was $164,725 (12-week) in GT1 non-cirrhotic patients, 
and $341,569 (24-week) in GT1 cirrhotic patients, all treatment histories combined. 
Long-term cost per SVR with SOF+PR was $116,713 in GT1a and $134,561 in GT1b 
naïve patients (12-week). CONCLUSIONS: The long-term cost per SVR was lower in 
non-cirrhotic than in cirrhotic patients across all regimens. The results of this study 
suggest that the use of Viekira Pak is a clinically and economically viable strategy 
for GT1 HCV treatment.
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OBJECTIVES: Hepatic encephalopathy (HE) is a major complication of liver disease 
and is becoming more problematic in an aging population with cirrhosis. Medicare 
is a United States (US) government-sponsored health insurance program that guar-
antees access to healthcare for all individuals 65 or older, or who are younger with 
disability. The objective of this study was to estimate the annual healthcare expen-
ditures of patients with HE from a Medicare perspective. METHODS: Inpatient, 
Outpatient, and Master Beneficiary Research Identifiable Files (RIFs) from the 
Medicare 5% Sample were utilized for this study. Medicare 5% Sample is a nation-
ally representative sample of healthcare claims data for the Medicare population. 
RIFs include procedure codes, diagnosis codes, reimbursement, and demographic 
information. To be eligible patients had to have a primary diagnosis code of HE dur-
ing an inpatient hospitalization. Healthcare utilization/expenditures for inpatient 
(IP) and outpatient (OP) procedures for the calendar year 2012 were estimated overall 
and by age cohorts: ≤ 62, 63-67, 68-72, 73-77, 78-82, 83+. RESULTS: A total of 1,113 
patients were identified with HE in 2012 (47% were male). 27% of the patients were 
≤ 62 years of age while 11% were 83 or older. The most common chronic comorbid 
condition was hypertension (75%) and 41% had renal failure. The mean total number 
of visits per HE patient was 13.4 (Mean number of IP and OP visits = 2.4 and 11.0, 
respectively) and varied across age cohorts 14.6 in the ≤ 62 cohort to 10.7 in the 83+ 
cohort; p< 0.0001. For patients who had an IP visit the mean length of stay was 5.9 
days. Mean inpatient expenditures ranged from $25,364 to $58,625 with the highest 
